NEW YORK (GenomeWeb News) - Canadian biomarker developer Med BioGene has hired an investment advisory and financial services company and has granted some of its executives options to buy up to 560,000 common shares at Can$.34 ($.32) a share, the company said today.
The Vancouver, BC-based MBI said it has hired Peterson Capital, an investment, financial services, and communications firm, for a monthly cash rate and the option to buy up to 100,000 shares at Can$.34 a share.
Erinn Broshko, MBI's CEO, said Peterson has "a great track record in assisting small cap companies with investor relations and corporate communications," and that the partnership will complement MBI's ongoing relations with the Howard Group, a financial relations company based in Calgary.